It protects against 15 serotypes. PCV20, also known as Prevnar 20, was licensed in 2021 for adults 18 years and older, then in 2023 was recommended for ages 6 weeks and up. It covers 20 serotypes.

Widespread use of PCV13, which covers additional serotypes 3, 6A and 19A, may contribute to reduce the clonal spread of drug-resistant 19A pneumococci. The author has no relevant affiliations or ...

“The change of vaccine occurs because the scientific evidence provided by the Committee shows that the PCV13 vaccine has a greater spectrum of coverage against the different serotypes of ...

emergence of non-PCV7 serotypes, especially 19A, is prominent worldwide, which also contributes to the increase in antimicrobial resistance and MDR in S. pneumoniae. PCV13 may contribute in ...